C. R. Bowen

Suggest Changes
Learn More
3071 Background: GW572016 is an oral, dual EGFR/ErbB2 tyrosine kinase inhibitor that blocks signal transduction pathways implicated in cancer growth. In vitro studies indicate that GW572016 is(More)